Celgene Unites With National Psoriasis
Foundation to Elevate Awareness of Psoriatic Arthritis (PsA) and
Rally Support for Patient Community
Celgene Corporation (NASDAQ: CELG) and the National Psoriasis
Foundation (NPF) have united to mark Wednesday, September 28th as
the first-ever Psoriatic Arthritis (PsA) Awareness Day—a day
dedicated to raising public awareness around the importance of
recognition, diagnosis, and treatment. People are encouraged to
join the movement at GoPsADay.com to learn factors associated with
PsA, help spread the word via their social channels, and to stand
up and be counted for those living with this disease.
More than 1 million Americans live with PsA, although this
number may be higher given it is often underreported and
misdiagnosed—particularly as symptoms are sometimes confused with
other types of arthritis such as rheumatoid arthritis, gout, and
reactive arthritis. Some factors associated with PsA include pitted
fingernails, swollen fingers and toes, foot pain, joint stiffness
and/or pain, and a personal or family history of psoriasis or
arthritis.
Early recognition, diagnosis, and treatment of psoriatic
arthritis is critical for anyone living with the disease. Those who
are experiencing any of the common symptoms of PsA should contact
their healthcare provider.
“Psoriatic arthritis can present significant challenges to those
living with the disease, including significant pain and swelling in
joints that may impact a person’s activities of daily living,” said
Madelaine Feldman, MD, rheumatologist. “While there is no cure, PsA
can be managed, which is why it is critical for people to know the
factors associated with PsA, talk with their healthcare provider to
obtain the right diagnosis, and determine a treatment plan that
works for them.”
“In 85 percent of PsA patients, psoriasis occurs before joint
disease, so it is critical for psoriasis patients to understand
factors associated with PsA,” said Randy Beranek, president and
CEO, National Psoriasis Foundation. “Through these efforts and
more, we hope to help improve understanding of the disease,
decrease time to diagnosis, and stress the critical importance of
early treatment to help lessen the impact on patients’ overall
quality of life.”
PsA Awareness Day is dedicated to education, empowerment, and
action for the PsA community. Here are some ways for people to get
involved and show their support:
- Visit GoPsADay.com to access
information and tools on diagnosis and guiding an active discussion
with your healthcare provider.
- Help spread the word via social
channels utilizing PsA Awareness Day social media toolkit assets,
including a “5 Factors Associated With PsA” infographic and
#PsADay16.
“Celgene is committed to addressing the needs of people living
with psoriatic arthritis, which means understanding every point of
the patient journey from diagnosis to treatment,” said Scott Smith,
President, Global Inflammation & Immunology, Celgene. “These
Psoriatic Arthritis Awareness Day efforts are just one step in
addressing these needs and an important collective initiative to
support the psoriatic community by recognizing those living with
PsA, raising awareness of the factors associated with PsA, and
providing much-needed education on the disease.”
To learn more about PsA and help spread the word about awareness
day efforts, visit GoPsADay.com.
About National Psoriasis Foundation
National Psoriasis Foundation (NPF) is the world's largest
nonprofit serving those with psoriasis and psoriatic arthritis. Our
priority is to provide the information and services people need to
take control of their condition, while increasing research to find
a cure. In addition to serving more than 2.1 million people
annually through our health education and advocacy initiatives, NPF
has funded more than $13 million in psoriatic disease research
grants and fellowships. Learn more about the National Psoriasis
Foundation at www.psoriasis.org or call 800-723-9166. Follow us on
Facebook and Twitter.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey,
is an integrated global biopharmaceutical company engaged primarily
in the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow
Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
“expects,” “anticipates,” “believes,” “intends,” “estimates,”
“plans,” “will,” “outlook” and similar expressions. Forward-looking
statements are based on management’s current plans, estimates,
assumptions, and projections, and speak only as of the date they
are made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and other reports filed with the Securities and
Exchange Commission.
© 2016 Celgene Corporation 08/16 USII-CELG160008c
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160913005849/en/
Investors:CelgenePatrick E. Flanigan III, 908-673-9969Vice
President, Investor RelationsorMedia:CelgeneCatherine Cantone,
732-564-3592Sr. Director, Corporate CommunicationsorNational
Psoriasis FoundationMeredith Mills, 503-546-8413
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024